Skip to content

Ouster OUST Royalties — Cumulative revenue recognized

Similar metrics at other companies

Abercrombie & Fitch logo
ANFRoyalty — Revenue
$15.75M+2.9%
Sarepta Therapeutics, Inc. logo
SRPTRoyalty Revenue — Royalty Revenue
$4.18M+5.8%
Ligand Pharmaceuticals logo
LGNDRoyalties — Total revenues and income
$42.96M+56.3%
Ultragenyx Pharmaceutical logo
RARERoyalty — Revenue
$47M-2.1%
AbCellera Biologics Inc. logo
ABCLLicensing and royalty revenue — Total Revenue
$191K+14.4%
Supernus Pharmaceuticals logo
SUPNLicense — Revenue recognized
$20M+433%

Other financials

Income statement

See full
Revenue$48.6M+48.9%
Gross profit$20.8M+54.6%
Operating income-$19.2M+19.4%
Net income-$17.5M+20.7%
EPS (diluted)-$0.28+33.3%

Balance sheet

See full
Cash & equivalents$18.3M-27.3%
Total debt$17.4M-8.3%
Total equity$275.6M+64.1%
Total assets$381.5M+42.0%

Cash flow

See full
Operating cash flow-$7.3M-49.2%
CapEx$2.6M+364%
Free cash flow-$9.8M-81.2%

Valuation

See full
Market cap$2.88B+139%
Enterprise value$2.87B+142%
P/S15.5×+5.3×

Profitability

See full
Gross margin49%+9.5pp
Operating margin-37.9%-13.7pp
Net margin-32.3%-12.1pp
FCF margin-37.4%+11.2pp

Returns & leverage

See full
Return on equity-27%-9.3pp
Debt / equity0.1×0.0×
Current ratio+0.4×

Where this comes from

Reported directly by Ouster in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized.

The official record: Ouster’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ouster's royalties — cumulative revenue recognized.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ouster's royalties — cumulative revenue recognized?
Ouster (OUST) reported royalties — cumulative revenue recognized of $16.1M in Q4 2025.
What does royalties — cumulative revenue recognized mean?
This metric measures the total historical revenue recognized from royalty-based agreements since the inception of the specific licensing program or product line. It provides a long-term view of the aggregate financial value generated by the company's intellectual property assets. This cumulative figure is essential for evaluating the total return on investment for research and development efforts that lead to licensable technology.